The abstract is read at the publisher; the summary is JClub's.
In severe alopecia areata (SALT score ≥50), oral upadacitinib 30mg (UPA30mg) had the highest estimated probability of achieving SALT score ≤20 at week 24 (54.2%).
- Why it matters: Head-to-head trials are limited for choosing among oral Janus kinase inhibitors for severe alopecia areata, so indirect comparisons are needed to guide treatment selection.
- What they did: A systematic review and Bayesian network meta-analysis used 7 phase 3 or 4 randomized trials (3739 patients) comparing baricitinib, ritlecitinib, deuruxolitinib, and upadacitinib, using week 12 and 24 hair regrowth outcomes.
- The result: Risk-difference credible intervals showed JAK inhibitors were significantly higher than placebo, and UPA30mg was significantly higher than other treatments, implying it may best support hair regrowth at week 24.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.